Please ensure Javascript is enabled for purposes of website accessibility

Co-Diagnostics Reports Surge in Demand for Coronavirus Tests

By Jim Crumly - Updated Mar 5, 2020 at 3:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's shares have soared though it has offered few specifics about the financial impact its COVID-19 products are having.

Shares of molecular diagnostics company Co-Diagnostics (CODX 4.47%) jumped 24% Thursday after the company reported a surge in demand for its tests for COVID-19. The wave of orders came following an announcement by the U.S. Food and Drug Administration last weekend that opened the door for labs to use the diagnostic tests they've developed before those tests get formal approval from the agency.

The change in FDA policy allows laboratories to use tests after in-house validation, and Co-Diagnostics said that it's receiving requests from U.S. clinical laboratories for reagents in preparation for patient testing. CEO Dwight Egan says his company is now manufacturing and shipping coronavirus products to countries on four continents, and it plans to triple its total manufacturing capacity for this test by bringing its facility in India into the effort.

Rising graph with paper airplane flying into the clouds.

Image source: Getty Images.

Co-Diagnostics stock has been on a wild ride recently as investors have scrambled to buy into companies that have opportunities to profit from fighting the COVID-19 epidemic. Shares of the company soared almost five-fold in the last two weeks and are up by more than 1,400% in 2020, making it one of the biggest winners from the outbreak.

However, the Utah-based company has been rather tight-lipped about actual financial results related to its coronavirus products, and it continues to take advantage of the rising stock price by issuing new shares for direct placement with its investors. Co-Diagnostics raised $4.2 million in a direct offering of common stock this week, after raising $10.2 million on Feb. 13 and $5 million on Jan. 28.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
$5.61 (4.47%) $0.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.